Florina Iulia Bura

@imibic.org

Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
GE09 Research in peritoneal and retroperitoneal oncological surgery, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain

Florina Iulia Bura


                  Download Compact PDF  
https://researchid.co/florina

RESEARCH, TEACHING, or OTHER INTERESTS

Biochemistry, Genetics and Molecular Biology, Cancer Research, Oncology, Drug Discovery
5

Scopus Publications

31

Scholar Citations

3

Scholar h-index

1

Scholar i10-index

Scopus Publications

  • Breaking the Mucin Barrier: A New Affinity Chromatography-Mass Spectrometry Approach to Unveil Potential Cell Markers and Pathways Altered in Pseudomyxoma Peritonei
    Antonio Romero-Ruiz, Melissa Granados-Rodríguez, Florina I. Bura, Francisca Valenzuela-Molina, Blanca Rufián-Andújar, Ana Martínez-López, Lidia Rodríguez-Ortiz, Rosa Ortega-Salas, María Torres-Martínez, Ana Moreno-Serrano, Justo Castaño, Carmen Michán, José Alhama, Mari C. Vázquez-Borrego, Álvaro Arjona-Sánchez
    Biological Procedures Online, 2024
    Background Pseudomyxoma peritonei (PMP) is a rare peritoneal mucinous carcinomatosis with largely unknown underlying molecular mechanisms. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the only therapeutic option; however, despite its use, recurrence with a fatal outcome is common. The lack of molecular characterisation of PMP and other mucinous tumours is mainly due to the physicochemical properties of mucin. Results This manuscript describes the first protocol capable of breaking the mucin barrier and isolating proteins from mucinous tumours. Briefly, mucinous tumour samples were homogenised and subjected to liquid chromatography using two specific columns to reduce mainly glycoproteins, albumins and immunoglobulin G. The protein fractions were then subjected to mass spectrometry analysis and the proteomic profile obtained was analysed using various bioinformatic tools. Thus, we present here the first proteome analysed in PMP and identified a distinct mucin isoform profile in soft compared to hard mucin tumour tissues as well as key biological processes/pathways altered in mucinous tumours. Importantly, this protocol also allowed us to identify MUC13 as a potential tumour cell marker in PMP. Conclusions In sum, our results demonstrate that this protein isolation protocol from mucin will have a high impact, allowing the oncology research community to more rapidly advance in the knowledge of PMP and other mucinous neoplasms, as well as develop new and effective therapeutic strategies.
  • Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination
    P. Villarejo Campos, M.C. Vázquez-Borrego, J. Martínez-Quintanilla, D. Cabot, A. Romero-Ruíz, M. Granados-Rodríguez, F.I. Bura, M. García-Arranz, D. García-Olmo, A. Arjona-Sánchez
    European Journal of Surgical Oncology, 2024
  • Intra-tumoural bromelain and N-acetylcysteine for recurrent and unresectable pseudomyxoma peritonei: phase I/II trial
    Lidia Rodríguez-Ortiz, Mari C Vázquez-Borrego, Florina I Bura, Melissa Granados-Rodríguez, Francisca Valenzuela-Molina, Blanca Rufián-Andújar, Ana Martínez-López, Rosa Ortega-Salas, Juan José Espejo-Herrero, Antonio Romero-Ruiz, Álvaro Arjona-Sánchez
    British Journal of Surgery, 2024
  • Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms
    Mari C. Vázquez-Borrego, Melissa Granados-Rodríguez, Florina I. Bura, Ana Martínez-López, Blanca Rufián-Andújar, Francisca Valenzuela-Molina, Lidia Rodríguez-Ortiz, Sergio Haro-Yuste, Ana Moreno-Serrano, Rosa Ortega-Salas, Rafael Pineda-Reyes, Carmen Michán, José Alhama, Antonio Romero-Ruiz, Álvaro Arjona-Sánchez
    Experimental Hematology and Oncology, 2023
    Pseudomyxoma peritonei (PMP) is a rare disease characterized by a massive accumulation of mucus in the peritoneal cavity. The only effective treatment is aggressive surgery, aimed at removing all visible tumors. However, a high percentage of patients relapse, with subsequent progression and death. Recently, there has been an increase in therapies that target mutated oncogenic proteins. In this sense, KRAS has been reported to be highly mutated in PMP, with KRASG12D being the most common subtype. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in a high-grade PMP xenograft mouse model carrying a KRASG12D mutation. The results obtained in this work showed a profound inhibition of tumor growth, which was associated with a reduction in cell proliferation, an increase in apoptosis, and a reduction in the MAPK and PI3K/AKT/mTOR signaling pathways. In conclusion, these results demonstrate the high potency and efficacy of MRTX1133 in KRASG12D-PMP tumors and provide a rationale for clinical trials.
  • Intraoperative oxygen tension and redox homeostasis in Pseudomyxoma peritonei: A short case series
    Francisca Valenzuela-Molina, Florina I. Bura, Mari C. Vázquez-Borrego, Melissa Granados-Rodríguez, Blanca Rufián-Andujar, Sebastián Rufián-Peña, Ángela Casado-Adam, Juan Manuel Sánchez-Hidalgo, Lidia Rodríguez-Ortiz, Rosa Ortega-Salas, Ana Martínez-López, Carmen Michán, José Alhama, Álvaro Arjona-Sánchez, Antonio Romero-Ruiz
    Frontiers in Oncology, 2023
    IntroductionPseudomyxoma peritonei (PMP) is a rare malignant disease characterized by a massive multifocal accumulation of mucin within the peritoneal cavity. The current treatment option is based on complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. However, the recurrence is frequent with subsequent progression and death. To date, most of the studies published in PMP are related to histological and genomic analyses. Thus, the need for further studies unveiling the underlying PMP molecular mechanisms is urgent. In this regard, hypoxia and oxidative stress have been extensively related to tumoral pathologies, although their contribution to PMP has not been elucidated.MethodsIn this manuscript, we have evaluated, for the first time, the intratumoral real-time oxygen microtension (pO2mt) in the tumor (soft and hard mucin) and surrounding healthy tissue from five PMP patients during surgery. In addition, we measured hypoxia (Hypoxia Inducible Factor-1a; HIF-1α) and oxidative stress (catalase; CAT) markers in soft and hard mucin from the same five PMP patient samples and in five control samples.ResultsThe results showed low intratumoral oxygen levels, which were associated with increased HIF-1α protein levels, suggesting the presence of a hypoxic environment in these tumors. We also found a significant reduction in CAT activity levels in soft and hard mucin compared with healthy tissue samples.DiscussionIn conclusion, our study provides the first evidence of low intratumoral oxygen levels in PMP patients associated with hypoxia and oxidative stress markers. However, further investigation is required to understand the potential role of oxidative stress in PMP in order to find new therapeutic strategies.

RECENT SCHOLAR PUBLICATIONS

  • Omic analysis of the protein profile in digestive tumours, from proteomics to clinical practice
    FI Bura, R Pezzopane, M Granados, L Rodríguez-Ortiz, B Rufián-Andújar, ...
    Cirugía Española (English Edition), 800303 , 2026
    2026
  • Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination
    PV Campos, MC Vázquez-Borrego, J Martínez-Quintanilla, D Cabot, ...
    European Journal of Surgical Oncology 50 (7), 108395 , 2024
    2024
    Citations: 2
  • Breaking the mucin barrier: a new affinity chromatography-mass spectrometry approach to unveil potential cell markers and pathways altered in pseudomyxoma peritonei
    A Romero-Ruiz, M Granados-Rodríguez, FI Bura, F Valenzuela-Molina, ...
    Biological Procedures Online 26 (1), 13 , 2024
    2024
    Citations: 3
  • Intra-tumoural bromelain and N -acetylcysteine for recurrent and unresectable pseudomyxoma peritonei: phase I/II trial
    L Rodríguez-Ortiz, MC Vázquez-Borrego, FI Bura, M Granados-Rodríguez, ...
    British Journal of Surgery 111 (3), znae045 , 2024
    2024
    Citations: 5
  • Antitumor effect of a small-molecule inhibitor of KRAS G12D in xenograft models of mucinous appendicular neoplasms
    MC Vázquez-Borrego, M Granados-Rodríguez, FI Bura, A Martínez-López, ...
    Experimental Hematology & Oncology 12 (1), 102 , 2023
    2023
    Citations: 10
  • Diseño y elaboración de un sérum facial con Lactobacillus fermentum CECT 5716
    F Iulia-Bura, E Ortega-Martínez, MA Ruiz-Martínez, ...
    Ars Pharmaceutica (Internet) 64 (3), 230-242 , 2023
    2023
    Citations: 1
  • External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
    A Arjona-Sanchez, A Martinez-López, MT Moreno-Montilla, J Mulsow, ...
    European Journal of Surgical Oncology 49 (8), 1481-1488 , 2023
    2023
    Citations: 6
  • Design and development of a facial Serum with Lactobacillus fermentum CECT 5716
    F Iulia-Bura, E Ortega-Martínez, MA Ruiz-Martínez, ...
    Universidad de Granada, Facultad de Farmacia. , 2023
    2023
    Citations: 1
  • Intraoperative oxygen tension and redox homeostasis in Pseudomyxoma peritonei: a short case series
    F Valenzuela-Molina, FI Bura, MC Vázquez-Borrego, ...
    Frontiers in oncology 13, 1076500 , 2023
    2023
    Citations: 3
  • Diagnóstico de fibromialgia: tendencias
    FI Bura
    2020

MOST CITED SCHOLAR PUBLICATIONS

  • Antitumor effect of a small-molecule inhibitor of KRAS G12D in xenograft models of mucinous appendicular neoplasms
    MC Vázquez-Borrego, M Granados-Rodríguez, FI Bura, A Martínez-López, ...
    Experimental Hematology & Oncology 12 (1), 102 , 2023
    2023
    Citations: 10
  • External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
    A Arjona-Sanchez, A Martinez-López, MT Moreno-Montilla, J Mulsow, ...
    European Journal of Surgical Oncology 49 (8), 1481-1488 , 2023
    2023
    Citations: 6
  • Intra-tumoural bromelain and N -acetylcysteine for recurrent and unresectable pseudomyxoma peritonei: phase I/II trial
    L Rodríguez-Ortiz, MC Vázquez-Borrego, FI Bura, M Granados-Rodríguez, ...
    British Journal of Surgery 111 (3), znae045 , 2024
    2024
    Citations: 5
  • Breaking the mucin barrier: a new affinity chromatography-mass spectrometry approach to unveil potential cell markers and pathways altered in pseudomyxoma peritonei
    A Romero-Ruiz, M Granados-Rodríguez, FI Bura, F Valenzuela-Molina, ...
    Biological Procedures Online 26 (1), 13 , 2024
    2024
    Citations: 3
  • Intraoperative oxygen tension and redox homeostasis in Pseudomyxoma peritonei: a short case series
    F Valenzuela-Molina, FI Bura, MC Vázquez-Borrego, ...
    Frontiers in oncology 13, 1076500 , 2023
    2023
    Citations: 3
  • Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination
    PV Campos, MC Vázquez-Borrego, J Martínez-Quintanilla, D Cabot, ...
    European Journal of Surgical Oncology 50 (7), 108395 , 2024
    2024
    Citations: 2
  • Diseño y elaboración de un sérum facial con Lactobacillus fermentum CECT 5716
    F Iulia-Bura, E Ortega-Martínez, MA Ruiz-Martínez, ...
    Ars Pharmaceutica (Internet) 64 (3), 230-242 , 2023
    2023
    Citations: 1
  • Design and development of a facial Serum with Lactobacillus fermentum CECT 5716
    F Iulia-Bura, E Ortega-Martínez, MA Ruiz-Martínez, ...
    Universidad de Granada, Facultad de Farmacia. , 2023
    2023
    Citations: 1
  • Omic analysis of the protein profile in digestive tumours, from proteomics to clinical practice
    FI Bura, R Pezzopane, M Granados, L Rodríguez-Ortiz, B Rufián-Andújar, ...
    Cirugía Española (English Edition), 800303 , 2026
    2026
  • Diagnóstico de fibromialgia: tendencias
    FI Bura
    2020